250 Pages Lung Cancer Diagnostics Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider
According to Fact MR’s recent market research, sales of Lung Cancer Diagnostics to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.
Focus on improving overall patient care will remain a chief growth driver. Besides this, Lung Cancer Diagnostics market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.
To remain ‘ahead’ of your competitors, request for a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=49
A newly published report by Fact.MR estimates the global lung cancer diagnostics market revenue to reach US$ 4 Bn by 2031, representing a 2x increase from 2020. Augmented development of lung cancer-specific biomarkers is propelling demand for the lung cancer diagnostics over the forecast period. Revenue from CA tests will account for US$ 1 Bn by 2031-end.
The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Lung Cancer Diagnostics market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Lung Cancer Diagnostics
The report offers actionable and valuable market insights of Lung Cancer Diagnostics. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Lung Cancer Diagnostics Market across various industries and regions.
This newly published and insightful report sheds light on Market Insights of Lung Cancer Diagnostics, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Lung Cancer Diagnostics Market.
Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=49
Segmentation:
-
Test Type
- CA Test for Lung Cancer Diagnostics
- HER2 Tests for Lung Cancer Diagnostics
- ALK Tests for Lung Cancer Diagnostics
- Angiogenesis Inhibitor for Lung Cancer Diagnostics
- EGFR Mutation Tests for Lung Cancer Diagnostics
- KRAS Mutation Tests for Lung Cancer Diagnostics
- Others
-
End-User
- Lung Cancer Diagnostics for Hospital Associated Labs
- Lung Cancer Diagnostics for Independent Diagnostic Laboratories
- Lung Cancer Diagnostics for Cancer Research Institutes
- Others
-
Indication
- Non-Small-cell Lung Cancer Diagnostics
- Small-cell Lung Cancer Diagnostics
Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/49
Key Takeaways from Market Study
- By test type, CA lung cancer diagnostic tests to reign supreme, clocking US$ 1 Bn by 2031
- Hospital-associated labs set to reach around US$ 1.6 Bn until 2031
- Treatment for non-small cell lung cancer (NSCLC) to comprise over 50% of total demand
- Cancer research institutes to make significant use of lung cancer diagnostics, expanding at 6% CAGR
- Angiogenesis inhibitors is the fastest growing segment followed by HER2 tests
- U.S to acquire around 27% market share in the global lung cancer diagnostics industry
- China is expected to register a CAGR of around 8% until 2031, with NSCLC treatment gaining traction
“Rapid technological advancements with respect to human diagnostics is prompting lung cancer diagnostics service providers to leverage key advancements, including AI and automation, opening lucrative growth frontiers,” comments a Fact.MR analyst.
Competitive Landscape
Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, technological advances for cancer screening, mergers, and acquisitions.
- In March 2021, Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. collaborated with Illumina, Inc. (to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina’s NextSeq™ 550Dx sequencing platform.
- In Jan 2017, Abbott Laboratories completed largest the acquisition of St.Jude Medical for US$ 25 Bn. Together, the company will compete in nearly every area of the $30 billion cardiovascular markets and hold the No. 1 or 2 positions across large and high-growth cardiovascular device markets.
Read More Trending Reports of Fact.MR-
https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/
Report Benefits & Key Questions Answered
- Lung Cancer Diagnostics Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
- Lung Cancer Diagnostics Historical volume analysis: The report provides a comparison of Lung Cancer Diagnostics’s historical sales and projected sales performance for 2021-2031.
- Lung Cancer Diagnostics Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Lung Cancer Diagnostics market. It carefully gauges the impact of changing healthcare needs of key demographics globally
- Lung Cancer Diagnostics Consumption by demographics: The report investigates consumer behavior affecting Lung Cancer Diagnostics demand outlook for the assessment period. Effect of their keenness for digital trends on Lung Cancer Diagnostics market is carefully analyzed
- Post COVID consumer spending on Lung Cancer Diagnostics: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Lung Cancer Diagnostics market growth.
More Valuable Insights on Lung Cancer Diagnostics Market
Fact.MR, in its new report, offers an unbiased Market Analysis of Lung Cancer Diagnostics, Sales and Demand of Lung Cancer Diagnostics, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.
Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:
Fluoro Enzymatic Assays Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031
Shower Chairs Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031
Infrared Thermometer Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates